Axa S.A. Lowers Stake in Thermo Fisher Scientific Inc. $TMO

Axa S.A. cut its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 15.9% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 437,727 shares of the medical research company’s stock after selling 82,824 shares during the period. Axa S.A. owned approximately 0.12% of Thermo Fisher Scientific worth $177,481,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in TMO. Norges Bank bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at approximately $2,264,615,000. Soundwatch Capital LLC acquired a new stake in Thermo Fisher Scientific during the second quarter valued at approximately $807,713,000. Flossbach Von Storch SE boosted its position in shares of Thermo Fisher Scientific by 93.0% in the 2nd quarter. Flossbach Von Storch SE now owns 2,727,021 shares of the medical research company’s stock valued at $1,105,698,000 after purchasing an additional 1,314,182 shares during the period. Arrowstreet Capital Limited Partnership grew its position in Thermo Fisher Scientific by 84.6% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,210,954 shares of the medical research company’s stock worth $490,993,000 after purchasing an additional 555,018 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of Thermo Fisher Scientific by 29.5% during the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,257,424 shares of the medical research company’s stock valued at $915,295,000 after acquiring an additional 514,399 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $567.87 on Tuesday. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97. The firm has a 50 day simple moving average of $561.82 and a 200 day simple moving average of $487.30. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The company has a market cap of $213.35 billion, a price-to-earnings ratio of 32.81, a PEG ratio of 4.19 and a beta of 0.90.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.50 by $0.29. The business had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.Thermo Fisher Scientific’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period last year, the company earned $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has initiated a stock repurchase program on Thursday, November 6th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical research company to purchase up to 2.4% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s board believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, December 15th. Thermo Fisher Scientific’s payout ratio is 9.94%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 10,225 shares of the firm’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $571.62, for a total value of $5,844,814.50. Following the completion of the transaction, the vice president owned 14,145 shares in the company, valued at $8,085,564.90. This trade represents a 41.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Frederick M. Lowery sold 6,913 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $597.68, for a total transaction of $4,131,761.84. Following the completion of the transaction, the executive vice president directly owned 14,367 shares of the company’s stock, valued at approximately $8,586,868.56. This represents a 32.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 149,271 shares of company stock valued at $86,507,282. 0.33% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

TMO has been the subject of several research analyst reports. Argus boosted their price objective on Thermo Fisher Scientific from $580.00 to $610.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. UBS Group increased their price objective on shares of Thermo Fisher Scientific from $500.00 to $590.00 and gave the stock a “neutral” rating in a report on Thursday, October 23rd. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, October 14th. Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the company an “outperform” rating in a research note on Tuesday, September 2nd. Finally, Hsbc Global Res upgraded Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a report on Monday, December 1st. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $609.38.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.